Astria Therapeutics Analyst Ratings
JMP Securities Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $26
Wedbush Initiates Astria Therapeutics Inc(ATXS.US) With Buy Rating, Announces Target Price $28
Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $32
Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating
LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $22
Astria Therapeutics Analyst Ratings
H.C. Wainwright Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $16
TD Cowen Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $35
TD Cowen Sticks to Its Buy Rating for Astria Therapeutics (ATXS)
JMP Securities Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $26
TD Cowen Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $35
LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $22
Astria Therapeutics Analyst Ratings
JMP Securities Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $26
H.C. Wainwright Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $16
JMP Securities Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $26
Astria Therapeutics Initiated at Market Outperform by JMP Securities
JMP Securities Initiates Astria Therapeutics Inc(ATXS.US) With Buy Rating, Announces Target Price $26
H.C. Wainwright Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $16